By Sriparna Roy Sept 17 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Ultragenyx Pharmaceutical's ...

Clinicians are far less religious than their patients. That gap shapes what gets discussed in therapy and what’s missed.

Starting hormone replacement therapy during perimenopause or early postmenopause may decrease cardiovascular disease risk by 22%, a new study suggests.

FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic ...

In published studies, including work by the investigators at the University of Utah, individuals treated with itPBM show ...

Sept 17 (Reuters) - Longeveron on Wednesday said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart ...

The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as ...

These specialists help analyze and solve design and organization problems that might be harming your well-being.

Should you save your most difficult conversations for your couples therapy sessions, or bring them up outside of therapy? One ...

Fluent therapy language can sound like opening up while doing the opposite. Here's how it keeps people at a distance, and what real disclosure asks instead.

This guide helps people interested in red light therapy for joint pain find the right fit. Take a look at our contenders’ strengths and weaknesses.

Fayuvi, previously known as UX111, uses an adeno-associated viral vector to deliver a working copy of the SGSH gene into the patient’s cells. It marks the first FDA-approved therapy designed to ...